Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice

Download All
Hear from experts how the latest data from ASCO 2021 inform therapeutic strategies for patients with R/R MM and how to evaluate novel combination therapeutic regimens. Review their insights in clinical commentaries, slides, a podcast, and an on-demand webcast from a live CCO webinar.
Paul G. Richardson, MD
Program Director
person default
Nina Shah, MD
Peter M. Voorhees, MD

On-Demand Webcast

Watch this on-demand webcast from a live webinar where 3 experts discuss the latest data for the management of patients with relapsed or refractory myeloma, including new data from ASCO 2021.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue